Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
[en] We report here the long-term follow-up of the only prospective randomized trial of autologous hematopoietic stem cell transplantation (auto-HSCT) with peripheral blood stem cells (APBSCT) versus auto-HSCT with bone marrow (ABMT) in acute myeloid leukemia (AML) patients in first remission (CR). We observed that among patients alive and still in CR 5 years after planned auto-HSCT, approximately 10% of the patients died in the following 10 years. This stresses the need for long-term close surveillance of AML patients after auto-HSCT. Further, long-term follow-up of the trial confirms that APBSCT was comparable to ABMT in term of disease-free-survival and overall survival.
Disciplines :
Hematology
Author, co-author :
Baron, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques
Efficace, Fabio ; Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy
Cannella, Laura; Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy
Stevens-Kroef, Marian; Radboud University Medical Center, Nijmegen, The Netherlands
Amadori, Sergio; Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy
de Witte, Theo; Radboud University Medical Center, Nijmegen, The Netherlands
Lübbert, Michael; Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
Venditti, Adriano ; Department of Hematology, Sapienza University, Rome, Italy
Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
The authors thank all the EORTC Leukemia Group and GIMEMA members and the clinicians who participated in this study. This publication was supported by a donation from the “Fondation contre le cancer” from Belgium. FB is a senior research associate of the Fund for Scientific Research (FRS‐FNRS) Belgium.
Passweg JR, Baldomero H, Ciceri F, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT Activity Survey. Bone Marrow Transplant. 2023;58:647-658.
Gorin N-C, Labopin M, Blaise D, et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol. 2009;27:3987-3993.
Baron F, Efficace F, Cannella L, et al. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: long-term follow up of a phase III study. Am J Hematol. 2020;95:749-758.
Hengeveld M, Suciu S, Chelgoum Y, et al. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT. Bone Marrow Transplant. 2015;50:341-347.
Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354-365.
Czerw T, Labopin M, Gorin N-C, et al. Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122:1880-1887.
